These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34151801)

  • 1. Salivaomics as a Potential Tool for Predicting Alzheimer's Disease During the Early Stages of Neurodegeneration.
    François M; Karpe A; Liu JW; Beale D; Hor M; Hecker J; Faunt J; Maddison J; Johns S; Doecke J; Rose S; Leifert WR
    J Alzheimers Dis; 2021; 82(3):1301-1313. PubMed ID: 34151801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Biomarkers of Alzheimer's Disease as Identified in Saliva using 1H NMR-Based Metabolomics.
    Yilmaz A; Geddes T; Han B; Bahado-Singh RO; Wilson GD; Imam K; Maddens M; Graham SF
    J Alzheimers Dis; 2017; 58(2):355-359. PubMed ID: 28453477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolomics Analyses of Saliva Detect Novel Biomarkers of Alzheimer's Disease.
    Huan T; Tran T; Zheng J; Sapkota S; MacDonald SW; Camicioli R; Dixon RA; Li L
    J Alzheimers Dis; 2018; 65(4):1401-1416. PubMed ID: 30175979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-Omics, an Integrated Approach to Identify Novel Blood Biomarkers of Alzheimer's Disease.
    François M; Karpe AV; Liu JW; Beale DJ; Hor M; Hecker J; Faunt J; Maddison J; Johns S; Doecke JD; Rose S; Leifert WR
    Metabolites; 2022 Oct; 12(10):. PubMed ID: 36295851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease Using Artificial Intelligence and Machine Learning.
    Yilmaz A; Ustun I; Ugur Z; Akyol S; Hu WT; Fiandaca MS; Mapstone M; Federoff H; Maddens M; Graham SF
    J Alzheimers Dis; 2020; 78(4):1381-1392. PubMed ID: 33164929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolome in progression to Alzheimer's disease.
    Orešič M; Hyötyläinen T; Herukka SK; Sysi-Aho M; Mattila I; Seppänan-Laakso T; Julkunen V; Gopalacharyulu PV; Hallikainen M; Koikkalainen J; Kivipelto M; Helisalmi S; Lötjönen J; Soininen H
    Transl Psychiatry; 2011 Dec; 1(12):e57. PubMed ID: 22832349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease.
    Gómez-Pascual A; Naccache T; Xu J; Hooshmand K; Wretlind A; Gabrielli M; Lombardo MT; Shi L; Buckley NJ; Tijms BM; Vos SJB; Ten Kate M; Engelborghs S; Sleegers K; Frisoni GB; Wallin A; Lleó A; Popp J; Martinez-Lage P; Streffer J; Barkhof F; Zetterberg H; Visser PJ; Lovestone S; Bertram L; Nevado-Holgado AJ; Gualerzi A; Picciolini S; Proitsi P; Verderio C; Botía JA; Legido-Quigley C
    Comput Biol Med; 2024 Jun; 176():108588. PubMed ID: 38761503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic Profiles Help Discriminate Mild Cognitive Impairment from Dementia Stage in Alzheimer's Disease.
    Jääskeläinen O; Hall A; Tiainen M; van Gils M; Lötjönen J; Kangas AJ; Helisalmi S; Pikkarainen M; Hallikainen M; Koivisto A; Hartikainen P; Hiltunen M; Ala-Korpela M; Soininen P; Soininen H; Herukka SK
    J Alzheimers Dis; 2020; 74(1):277-286. PubMed ID: 32007958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acyl-Alkyl-Phosphatidlycholines are Decreased in Saliva of Patients with Alzheimer's Disease as Identified by Targeted Metabolomics.
    Marksteiner J; Oberacher H; Humpel C
    J Alzheimers Dis; 2019; 68(2):583-589. PubMed ID: 30814361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet biomarkers for a descending cognitive function: A proteomic approach.
    Yu H; Liu Y; He B; He T; Chen C; He J; Yang X; Wang JZ
    Aging Cell; 2021 May; 20(5):e13358. PubMed ID: 33942972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Depressive Symptoms on Conversion from Mild Cognitive Impairment Subtypes to Alzheimer's Disease: A Community-Based Longitudinal Study.
    Kida J; Nemoto K; Ikejima C; Bun S; Kakuma T; Mizukami K; Asada T
    J Alzheimers Dis; 2016; 51(2):405-15. PubMed ID: 26890740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma metabolic profiling of mild cognitive impairment and Alzheimer's disease using liquid chromatography/mass spectrometry.
    Liu Y; Li N; Zhou L; Li Q; Li W
    Cent Nerv Syst Agents Med Chem; 2014; 14(2):113-20. PubMed ID: 25515716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Profiling of Neocortical Tissue Discriminates Alzheimer's Disease from Mild Cognitive Impairment, High Pathology Controls, and Normal Controls.
    Jasbi P; Shi X; Chu P; Elliott N; Hudson H; Jones D; Serrano G; Chow B; Beach TG; Liu L; Jentarra G; Gu H
    J Proteome Res; 2021 Sep; 20(9):4303-4317. PubMed ID: 34355917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum metabolomic profiling in patients with Alzheimer disease and amnestic mild cognitive impairment by GC/MS.
    Sun C; Gao M; Wang F; Yun Y; Sun Q; Guo R; Yan C; Sun X; Li Y
    Biomed Chromatogr; 2020 Sep; 34(9):e4875. PubMed ID: 32384189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment.
    Wang G; Zhou Y; Huang FJ; Tang HD; Xu XH; Liu JJ; Wang Y; Deng YL; Ren RJ; Xu W; Ma JF; Zhang YN; Zhao AH; Chen SD; Jia W
    J Proteome Res; 2014 May; 13(5):2649-58. PubMed ID: 24694177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics.
    Trushina E; Dutta T; Persson XM; Mielke MM; Petersen RC
    PLoS One; 2013; 8(5):e63644. PubMed ID: 23700429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-omics signature of brain amyloid deposition in asymptomatic individuals at-risk for Alzheimer's disease: The INSIGHT-preAD study.
    Xicota L; Ichou F; Lejeune FX; Colsch B; Tenenhaus A; Leroy I; Fontaine G; Lhomme M; Bertin H; Habert MO; Epelbaum S; Dubois B; Mochel F; Potier MC;
    EBioMedicine; 2019 Sep; 47():518-528. PubMed ID: 31492558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
    Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K
    Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.